RHB-105 is an antibiotics and proton pump inhibitor (PPI) proprietary drug combination for Helicobacter Pylori (H. Pylori) infection. RHB-105 was acquired from Sydney-based Giaconda [ASX: GIA] in August 2010. RHB-105 is an antibiotics and PPI combination for treatment of H. Pylori infections which are resistant to currently approved antibiotics combination packs. H. Pylori is known to be the major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (MALT) lymphoma. Following favorable interim results in a phase IIa study, RedHill is currently executing its development plan.
Latest News
-
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting) -
February 7th, 2012
RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) -
February 2nd, 2012
Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) -
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
See More News